CannaMore Biotechs
CannaMore Completes Successful Clinical Trial
for novel formulation of Cannabidiol for Ulcerative Colitis
Mor Research Applications
Met Mor’s team at HLTH Europe 2024, June 17-20, Amsterdam
Companies and investors interested in meeting please contact: sari@mor-research.com
Can-Fite
FDA grants IND clearance
For NAMODENOSON to treat MASH patients in phase IIb study
Met Mor’s team at BIOMED 2024, May 21-23, Tel Aviv
Companies, entrepreneurs and investors please contact: sari@mor-research.com
EyeYon Medical
Early Outcomes of study with synthetic endothelial replacement membrane
The implant improves central corneal transparency and visual acuity in patients with failed EK
CAN-FITE submits IND application to FDA
to conduct phase IIb trial of Namodenoson in MASH patients
Mediwound
NexoBrid BLA to Include Pediatric Patients
FDA has Accepted for Review the Supplement to NexoBrid for Pediatric Patients with Severe Thermal Burns
Met Mor’s team at Mixiii 2024, March 5-6, Jerusalem
NGS Solutions
NGS’ Healthy Heights Available at Walmart
Walmart now stocking Healthy Heights with significant opportunities for expansion
IIA invests 25M NIS in innovation center in Be’er Sheva
Synergy 7 jointly owned by Mor, Ben Gurion U, B.G. Negev, Soroka , Elbit , Incubit Technological Entrepreneurship and Merage
